Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

por Bigaud, Marc, Ramseier, Pamela, Tisserand, Sarah, Lang, Meike, Urban, Beatrice, Beerli, Christian, Karlsson, Göril
Publicado 2023

Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

por Nuesslein-Hildesheim, Barbara, Ferrero, Enrico, Schmid, Cindy, Huck, Catherine, Smith, Paul, Tisserand, Sarah, Rubert, Joelle, Bornancin, Frederic, Eichlisberger, Denis, Cenni, Bruno
Publicado 2023

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models

por Dietrich, Michael, Hecker, Christina, Martin, Elodie, Langui, Dominique, Gliem, Michael, Stankoff, Bruno, Lubetzki, Catherine, Gruchot, Joel, Göttle, Peter, Issberner, Andrea, Nasiri, Milad, Ramseier, Pamela, Beerli, Christian, Tisserand, Sarah, Beckmann, Nicolau, Shimshek, Derya, Petzsch, Patrick, Akbar, David, Levkau, Bodo, Stark, Holger, Köhrer, Karl, Hartung, Hans-Peter, Küry, Patrick, Meuth, Sven Günther, Bigaud, Marc, Zalc, Bernard, Albrecht, Philipp
Publicado 2022